Search Results - "Gokhale, Prafulla C"

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway by Kurppa, Kari J., Liu, Yao, To, Ciric, Zhang, Tinghu, Fan, Mengyang, Vajdi, Amir, Knelson, Erik H., Xie, Yingtian, Lim, Klothilda, Cejas, Paloma, Portell, Andrew, Lizotte, Patrick H., Ficarro, Scott B., Li, Shuai, Chen, Ting, Haikala, Heidi M., Wang, Haiyun, Bahcall, Magda, Gao, Yang, Shalhout, Sophia, Boettcher, Steffen, Shin, Bo Hee, Thai, Tran, Wilkens, Margaret K., Tillgren, Michelle L., Mushajiang, Mierzhati, Xu, Man, Choi, Jihyun, Bertram, Arrien A., Ebert, Benjamin L., Beroukhim, Rameen, Bandopadhayay, Pratiti, Awad, Mark M., Gokhale, Prafulla C., Kirschmeier, Paul T., Marto, Jarrod A., Camargo, Fernando D., Haq, Rizwan, Paweletz, Cloud P., Wong, Kwok-Kin, Barbie, David A., Long, Henry W., Gray, Nathanael S., Jänne, Pasi A.

“…Eradicating tumor dormancy that develops following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment of EGFR-mutant non-small…”
Get full text

Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs by Flavahan, William A., Drier, Yotam, Johnstone, Sarah E., Hemming, Matthew L., Tarjan, Daniel R., Hegazi, Esmat, Shareef, Sarah J., Javed, Nauman M., Raut, Chandrajit P., Eschle, Benjamin K., Gokhale, Prafulla C., Hornick, Jason L., Sicinska, Ewa T., Demetri, George D., Bernstein, Bradley E.

“…Epigenetic aberrations are widespread in cancer, yet the underlying mechanisms and causality remain poorly understood 1 – 3 . A subset of gastrointestinal…”
Get full text

Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma by Iorgulescu, J Bryan, Gokhale, Prafulla C, Speranza, Maria C, Eschle, Benjamin K, Poitras, Michael J, Wilkens, Margaret K, Soroko, Kara M, Chhoeu, Chhayheng, Knott, Aine, Gao, Yan, Lim-Fat, Mary Jane, Baker, Gregory J, Bonal, Dennis M, Nguyen, Quang-Dé, Grant, Gareth R L, Ligon, Keith L, Sorger, Peter K, Chiocca, E Antonio, Anderson, Ana C, Kirschmeier, Paul T, Sharpe, Arlene H, Freeman, Gordon J, Reardon, David A

“…Dexamethasone, a uniquely potent corticosteroid, is frequently administered to patients with brain tumors to decrease tumor-associated edema, but limited data…”
Get full text

Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity by Mahadevan, Navin R, Knelson, Erik H, Wolff, Jacquelyn O, Vajdi, Amir, Saigí, Maria, Campisi, Marco, Hong, Deli, Thai, Tran C, Piel, Brandon, Han, Saemi, Reinhold, Bruce B, Duke-Cohan, Jonathan S, Poitras, Michael J, Taus, Luke J, Lizotte, Patrick H, Portell, Andrew, Quadros, Victor, Santucci, Alison D, Murayama, Takahiko, Cañadas, Israel, Kitajima, Shunsuke, Akitsu, Aoi, Fridrikh, Maya, Watanabe, Hideo, Reardon, Brendan, Gokhale, Prafulla C, Paweletz, Cloud P, Awad, Mark M, Van Allen, Eliezer M, Lako, Ana, Wang, Xi-Tao, Chen, Benjamin, Hong, Fangxin, Sholl, Lynette M, Tolstorukov, Michael Y, Pfaff, Kathleen, Jänne, Pasi A, Gjini, Evisa, Edwards, Robin, Rodig, Scott, Reinherz, Ellis L, Oser, Matthew G, Barbie, David A

“…Small cell lung carcinoma (SCLC) is highly mutated, yet durable response to immune checkpoint blockade (ICB) is rare. SCLC also exhibits cellular plasticity,…”
Get more information

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model by Reardon, David A, Gokhale, Prafulla C, Klein, Sarah R, Ligon, Keith L, Rodig, Scott J, Ramkissoon, Shakti H, Jones, Kristen L, Conway, Amy Saur, Liao, Xiaoyun, Zhou, Jun, Wen, Patrick Y, Van Den Abbeele, Annick D, Hodi, F Stephen, Qin, Lei, Kohl, Nancy E, Sharpe, Arlene H, Dranoff, Glenn, Freeman, Gordon J

“…Inhibition of immune checkpoints, including cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and its ligand PD-L1, has demonstrated…”
Get more information

Inhibition of USP10 induces degradation of oncogenic FLT3 by Weisberg, Ellen L, Schauer, Nathan J, Yang, Jing, Lamberto, Ilaria, Doherty, Laura, Bhatt, Shruti, Nonami, Atsushi, Meng, Chengcheng, Letai, Anthony, Wright, Renee, Tiv, Hong, Gokhale, Prafulla C, Ritorto, Maria Stella, De Cesare, Virginia, Trost, Matthias, Christodoulou, Alexandra, Christie, Amanda, Weinstock, David M, Adamia, Sophia, Stone, Richard, Chauhan, Dharminder, Anderson, Kenneth C, Seo, Hyuk-Soo, Dhe-Paganon, Sirano, Sattler, Martin, Gray, Nathanael S, Griffin, James D, Buhrlage, Sara J

“…An inhibitor of the deubiquitinase (DUB) USP10 regulates the degradation of oncogenic FLT3, thus defining USP10 as a DUB for FLT3 and providing a therapeutic…”
Get full text

Combined targeting of the BRD4-NUT-p300 axis in NUT midline carcinoma by dual selective bromodomain inhibitor, NEO2734 by Morrison-Smith, Chevaun D, Knox, Tatiana M, Filic, Ivona, Soroko, Kara M, Eschle, Benjamin K, Wilkens, Margaret K, Gokhale, Prafulla C, Giles, Francis, Griffin, Andrew, Brown, Bill, Shapiro, Geoffrey I, Zucconi, Beth E, Cole, Philip A, Lemieux, Madeleine E, French, Christopher A

“…NUT midline carcinoma (NMC) is a rare, aggressive subtype of squamous carcinoma that is driven by the BRD4-NUT fusion oncoprotein. BRD4, a BET protein, binds…”
Get full text

EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd by Haikala, Heidi M, Lopez, Timothy, Köhler, Jens, Eser, Pinar O, Xu, Man, Zeng, Qing, Teceno, Tyler J, Ngo, Kenneth, Zhao, Yutong, Ivanova, Elena V, Bertram, Arrien A, Leeper, Brittaney A, Chambers, Emily S, Adeni, Anika E, Taus, Luke J, Kuraguchi, Mari, Kirschmeier, Paul T, Yu, Channing, Shiose, Yoshinobu, Kamai, Yasuki, Qiu, Yang, Paweletz, Cloud P, Gokhale, Prafulla C, Jänne, Pasi A

“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are the standard-of-care treatment for -mutant non-small cell lung cancers (NSCLC)…”
Get full text

Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer by Nardi, Francesca, Perurena, Naiara, Schade, Amy E, Li, Ze-Hua, Ngo, Kenneth, Ivanova, Elena V, Saldanha, Aisha, Li, Chendi, Gokhale, Prafulla C, Hata, Aaron N, Barbie, David A, Paweletz, Cloud P, Jänne, Pasi A, Cichowski, Karen

“…Despite the success of KRAS G12C inhibitors in non-small cell lung cancer (NSCLC), more effective treatments are needed. One preclinical strategy has been to…”
Get full text

MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer by Yoshida, Ryohei, Saigi, Maria, Tani, Tetsuo, Springer, Benjamin F, Shibata, Hirofumi, Kitajima, Shunsuke, Mahadevan, Navin R, Campisi, Marco, Kim, William, Kobayashi, Yoshihisa, Thai, Tran C, Haratani, Koji, Yamamoto, Yurie, Sundararaman, Shriram K, Knelson, Erik H, Vajdi, Amir, Canadas, Israel, Uppaluri, Ravindra, Paweletz, Cloud P, Miret, Juan J, Lizotte, Patrick H, Gokhale, Prafulla C, Jänne, Pasi A, Barbie, David A

“…Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer. Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been…”
Get full text

Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer by Buck, Elizabeth, Gokhale, Prafulla C, Koujak, Susan, Brown, Eric, Eyzaguirre, Alexandra, Tao, Nianjun, Rosenfeld-Franklin, Maryland, Lerner, Lorena, Chiu, M Isabel, Wild, Robert, Epstein, David, Pachter, Jonathan A, Miglarese, Mark R

“…Insulin-like growth factor-1 receptor (IGF-1R) is a receptor tyrosine kinase (RTK) and critical activator of the phosphatidylinositol 3-kinase-AKT pathway…”
Get full text

Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin by Bhagwat, Shripad V, Gokhale, Prafulla C, Crew, Andrew P, Cooke, Andy, Yao, Yan, Mantis, Christine, Kahler, Jennifer, Workman, Jennifer, Bittner, Mark, Dudkin, Lorina, Epstein, David M, Gibson, Neil W, Wild, Robert, Arnold, Lee D, Houghton, Peter J, Pachter, Jonathan A

“…The phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway is frequently activated in human cancers, and mTOR is a clinically validated target. mTOR forms two…”
Get full text

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer by To, Ciric, Beyett, Tyler S, Jang, Jaebong, Feng, William W, Bahcall, Magda, Haikala, Heidi M, Shin, Bo H, Heppner, David E, Rana, Jaimin K, Leeper, Brittaney A, Soroko, Kara M, Poitras, Michael J, Gokhale, Prafulla C, Kobayashi, Yoshihisa, Wahid, Kamal, Kurppa, Kari J, Gero, Thomas W, Cameron, Michael D, Ogino, Atsuko, Mushajiang, Mierzhati, Xu, Chunxiao, Zhang, Yanxi, Scott, David A, Eck, Michael J, Gray, Nathanael S, Jänne, Pasi A

“…Epidermal growth factor receptor (EGFR) therapy using small-molecule tyrosine kinase inhibitors (TKIs) is initially efficacious in patients with EGFR-mutant…”
Get full text

Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling by Fan, Mengyang, Lu, Wenchao, Che, Jianwei, Kwiatkowski, Nicholas P, Gao, Yang, Seo, Hyuk-Soo, Ficarro, Scott B, Gokhale, Prafulla C, Liu, Yao, Geffken, Ezekiel A, Lakhani, Jimit, Song, Kijun, Kuljanin, Miljan, Ji, Wenzhi, Jiang, Jie, He, Zhixiang, Tse, Jason, Boghossian, Andrew S, Rees, Matthew G, Ronan, Melissa M, Roth, Jennifer A, Mancias, Joseph D, Marto, Jarrod A, Dhe-Paganon, Sirano, Zhang, Tinghu, Gray, Nathanael S

“…The transcription factor TEAD, together with its coactivator YAP/TAZ, is a key transcriptional modulator of the Hippo pathway. Activation of TEAD transcription…”
Get full text

Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma by Bandopadhayay, Pratiti, Piccioni, Federica, O’Rourke, Ryan, Ho, Patricia, Gonzalez, Elizabeth M., Buchan, Graham, Qian, Kenin, Gionet, Gabrielle, Girard, Emily, Coxon, Margo, Rees, Matthew G., Brenan, Lisa, Dubois, Frank, Shapira, Ofer, Greenwald, Noah F., Pages, Melanie, Balboni Iniguez, Amanda, Paolella, Brenton R., Meng, Alice, Sinai, Claire, Roti, Giovanni, Dharia, Neekesh V., Creech, Amanda, Tanenbaum, Benjamin, Khadka, Prasidda, Tracy, Adam, Tiv, Hong L., Hong, Andrew L., Coy, Shannon, Rashid, Rumana, Lin, Jia-Ren, Cowley, Glenn S., Lam, Fred C., Goodale, Amy, Lee, Yenarae, Schoolcraft, Kathleen, Vazquez, Francisca, Hahn, William C., Tsherniak, Aviad, Bradner, James E., Yaffe, Michael B., Milde, Till, Pfister, Stefan M., Qi, Jun, Schenone, Monica, Carr, Steven A., Ligon, Keith L., Kieran, Mark W., Santagata, Sandro, Olson, James M., Gokhale, Prafulla C., Jaffe, Jacob D., Root, David E., Stegmaier, Kimberly, Johannessen, Cory M., Beroukhim, Rameen

“…BET-bromodomain inhibition (BETi) has shown pre-clinical promise for MYC-amplified medulloblastoma. However, the mechanisms for its action, and ultimately for…”
Get full text

Reduced VEGF Production, Angiogenesis, and Vascular Regrowth Contribute to the Antitumor Properties of Dual mTORC1/mTORC2 Inhibitors by FALCON, Beverly L, BARR, Sharon, GOKHALE, Prafulla C, CHOU, Jeyling, FOGARTY, Jennifer, DEPEILLE, Philippe, MIGLARESE, Mark, EPSTEIN, David M, MCDONALD, Donald M

“…The mammalian target of rapamycin (mTOR) pathway is implicated widely in cancer pathophysiology. Dual inhibition of the mTOR kinase complexes mTORC1 and mTORC2…”
Get full text

Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine by Howard, Thomas P, Oberlick, Elaine M, Rees, Matthew G, Arnoff, Taylor E, Pham, Minh-Tam, Brenan, Lisa, DoCarmo, Mariana, Hong, Andrew L, Kugener, Guillaume, Chou, Hsien-Chao, Drosos, Yiannis, Mathias, Kaeli M, Ramos, Pilar, Seashore-Ludlow, Brinton, Giacomelli, Andrew O, Wang, Xiaofeng, Freeman, 3rd, Burgess B, Blankenship, Kaley, Hoffmann, Lauren, Tiv, Hong L, Gokhale, Prafulla C, Johannessen, Cory M, Stewart, Elizabeth A, Schreiber, Stuart L, Hahn, William C, Roberts, Charles W M

“…Rhabdoid tumors are devastating pediatric cancers in need of improved therapies. We sought to identify small molecules that exhibit and efficacy against…”
Get full text

Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations by Ogino, Atsuko, Choi, Jihyun, Lin, Mika, Wilkens, Margaret K., Calles, Antonio, Xu, Man, Adeni, Anika E., Chambers, Emily S., Capelletti, Marzia, Butaney, Mohit, Gray, Nathanael S., Gokhale, Prafulla C., Palakurthi, Sangeetha, Kirschmeier, Paul, Oxnard, Geoffrey R., Sholl, Lynette M., Jänne, Pasi A.

“…Small‐cell lung cancer (SCLC) occurs infrequently in never/former light smokers. We sought to study this rare clinical subset through next‐generation…”
Get full text

Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition by Hong, Andrew L, Tseng, Yuen-Yi, Wala, Jeremiah A, Kim, Won-Jun, Kynnap, Bryan D, Doshi, Mihir B, Kugener, Guillaume, Sandoval, Gabriel J, Howard, Thomas P, Li, Ji, Yang, Xiaoping, Tillgren, Michelle, Ghandi, Mahmhoud, Sayeed, Abeer, Deasy, Rebecca, Ward, Abigail, McSteen, Brian, Labella, Katherine M, Keskula, Paula, Tracy, Adam, Connor, Cora, Clinton, Catherine M, Church, Alanna J, Crompton, Brian D, Janeway, Katherine A, Van Hare, Barbara, Sandak, David, Gjoerup, Ole, Bandopadhayay, Pratiti, Clemons, Paul A, Schreiber, Stuart L, Root, David E, Gokhale, Prafulla C, Chi, Susan N, Mullen, Elizabeth A, Roberts, Charles Wm, Kadoch, Cigall, Beroukhim, Rameen, Ligon, Keith L, Boehm, Jesse S, Hahn, William C

“…Renal medullary carcinoma (RMC) is a rare and deadly kidney cancer in patients of African descent with sickle cell trait. We have developed faithful…”
Get full text

Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model by Iorgulescu, J Bryan, Ruthen, Neil, Ahn, Ryuhjin, Panagioti, Eleni, Gokhale, Prafulla C, Neagu, Martha, Speranza, Maria C, Eschle, Benjamin K, Soroko, Kara M, Piranlioglu, Raziye, Datta, Meenal, Krishnan, Shanmugarajan, Yates, Kathleen B, Baker, Gregory J, Jain, Rakesh K, Suvà, Mario L, Neuberg, Donna, White, Forest M, Chiocca, E Antonio, Freeman, Gordon J, Sharpe, Arlene H, Wu, Catherine J, Reardon, David A

“…The GL261 and CT2A syngeneic tumor lines are frequently used as immunocompetent orthotopic mouse models of human glioblastoma (huGBM) but demonstrate distinct…”
Get full text